Global Impetigo Treatment Market 2019-2023: Low Cost of Treatment / Side Effects of Drugs / Competitive Landscape - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Global Impetigo Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The impetigo treatment market will register a CAGR of about 7% by 2023.
The evolving resistance of microorganisms is likely to push growth in the market. There has been evolving resistance owing to the frequent usage of oral antibiotics. Hence manufacturers are developing more effective antibiotics to treat skin infections.
Low cost of treatment
Impetigo is a common, highly contagious bacterial skin infection. However, the infection can be treated easily without spending much.
Side effects of drugs
Impetigo is a bacterial infection of the skin which is treated with topical antibiotics or oral drugs. However, few side effects of these drugs may pose a challenge to the market.
The market appears to be fragmented and with the presence of several companies including Cutanea Life Sciences and GlaxoSmithKline, the competitive environment is quite intense.
Factors such as the low cost of treatment and the low cost of treatment, will provide considerable growth opportunities to impetigo treatment manufactures. Cutanea Life Sciences, GlaxoSmithKline, LEO Pharma, and Medimetriks Pharmaceuticals are some of the major companies covered in this report.
With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZINGMarket sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 07: MARKET SEGMENTATION BY PRODUCTMarket segmentation by product Comparison by product Topical - Market size and forecast 2018-2023 Oral - Market size and forecast 2018-2023 Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: SEGMENTATION BY DRUG CLASS
PART 10: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Key leading countries Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Cutanea Life Sciences GlaxoSmithKline LEO Pharma Medimetriks Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/h2n8rz/global_impetigo?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005639/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Dermatological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 12:40 PM/DISC: 12/19/2018 12:40 PM